Polymeric Curcumin Nanoparticles by a Facile in Situ Method for Macrophage Targeted Delivery

Overview

Journal Bioeng Transl Med

Date 2019 Jan 26

PMID 30680325

Citations 7

Authors

Priyanka S Jahagirdar

Pramod K Gupta

Savita P Kulkarni

Padma V Devarajan

Affiliations

Soon will be listed here.

Abstract

Targeting macrophages is a promising strategy for improved therapy of intracellular infections as macrophages exhibit rapid phagocytosis of particles >200 nm. Entrapment of Curcumin (CUR) in nanocarriers could provide bioenhancement and macrophage targeting. We present a simple and facile nanoprecipitation approach for instantaneous and on-site generation of curcumin nanoparticles (ISCurNP). ISCurNP optimised by Box-Behnken design exhibited average size of 208.25 ± 7.55 nm and entrapment efficiency of 90.16 ± 1.17%. Differential scanning calorimetry and X-Ray diffraction confirmed amorphization of CUR in ISCurNP. Sustained release was observed over 72 hr at lysosomal pH 4.5. Rapid and high uptake in RAW 264.7 macrophages was confirmed by flow cytometry and high performance liquid chromatography. Confocal microscopy established localisation of ISCurNP in lysosomal compartment. The facile nanoprecipitation method provides simple, scalable technology to enable macrophage targeted delivery of CUR, with great promise for improved therapy of intracellular infections.

Citing Articles

Oral In-Situ Nanoplatform with Balanced Hydrophobic-Hydrophilic Property for Transport Across Gastrointestinal Mucosa.

Attar E, Jayakumar S, Devarajan P AAPS PharmSciTech. 2024; 25(5):113.

PMID: 38750336 DOI: 10.1208/s12249-024-02824-8.

Enhancing the Bioavailability and Bioactivity of Curcumin for Disease Prevention and Treatment.

Bertoncini-Silva C, Vlad A, Ricciarelli R, Giacomo Fassini P, Suen V, Zingg J Antioxidants (Basel). 2024; 13(3).

PMID: 38539864 PMC: 10967568. DOI: 10.3390/antiox13030331.

Macrophage targeted polymeric curcumin nanoparticles limit intracellular survival of through induction of autophagy and augment anti-TB activity of isoniazid in RAW 264.7 macrophages.

Gupta P, Jahagirdar P, Tripathi D, Devarajan P, Kulkarni S Front Immunol. 2023; 14:1233630.

PMID: 37583694 PMC: 10424441. DOI: 10.3389/fimmu.2023.1233630.

Polymeric Nanoparticles for Delivery of Natural Bioactive Agents: Recent Advances and Challenges.

Elmowafy M, Shalaby K, Elkomy M, Alsaidan O, Gomaa H, Abdelgawad M Polymers (Basel). 2023; 15(5).

PMID: 36904364 PMC: 10007077. DOI: 10.3390/polym15051123.

Recent Advances in Polymeric Nanoparticle-Encapsulated Drugs against Intracellular Infections.

Sanchez A, Mejia S, Orozco J Molecules. 2020; 25(16).

PMID: 32824757 PMC: 7464666. DOI: 10.3390/molecules25163760.

References

Duvoix A, Blasius R, Delhalle S, Schnekenburger M, Morceau F, Henry E . Chemopreventive and therapeutic effects of curcumin. Cancer Lett. 2005; 223(2):181-90. DOI: 10.1016/j.canlet.2004.09.041. View

Shen H, Ackerman A, Cody V, Giodini A, Hinson E, Cresswell P . Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology. 2006; 117(1):78-88. PMC: 1782199. DOI: 10.1111/j.1365-2567.2005.02268.x. View

Menon V, Sudheer A . Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol. 2007; 595:105-25. DOI: 10.1007/978-0-387-46401-5_3. View

Anand P, Kunnumakkara A, Newman R, Aggarwal B . Bioavailability of curcumin: problems and promises. Mol Pharm. 2007; 4(6):807-18. DOI: 10.1021/mp700113r. View

Esmaeili F, Ghahremani M, Esmaeili B, Khoshayand M, Atyabi F, Dinarvand R . PLGA nanoparticles of different surface properties: preparation and evaluation of their body distribution. Int J Pharm. 2007; 349(1-2):249-55. DOI: 10.1016/j.ijpharm.2007.07.038. View

Hao J, Fang X, Zhou Y, Wang J, Guo F, Li F . Development and optimization of solid lipid nanoparticle formulation for ophthalmic delivery of chloramphenicol using a Box-Behnken design. Int J Nanomedicine. 2011; 6:683-92. PMC: 3084315. DOI: 10.2147/IJN.S17386. View

Kalepu S, Nekkanti V . Insoluble drug delivery strategies: review of recent advances and business prospects. Acta Pharm Sin B. 2015; 5(5):442-53. PMC: 4629443. DOI: 10.1016/j.apsb.2015.07.003. View

Senna J, Nogueira Barradas T, Cardoso S, Castiglione T, Serpe M, de Holanda E Silva K . Dual alginate-lipid nanocarriers as oral delivery systems for amphotericin B. Colloids Surf B Biointerfaces. 2018; 166:187-194. DOI: 10.1016/j.colsurfb.2018.03.015. View

Guhagarkar S, Malshe V, Devarajan P . Nanoparticles of polyethylene sebacate: a new biodegradable polymer. AAPS PharmSciTech. 2009; 10(3):935-42. PMC: 2802147. DOI: 10.1208/s12249-009-9284-4. View

10.

Bai X, Oberley-Deegan R, Bai A, Ovrutsky A, Kinney W, Weaver M . Curcumin enhances human macrophage control of Mycobacterium tuberculosis infection. Respirology. 2016; 21(5):951-7. DOI: 10.1111/resp.12762. View

11.

Chen H, Khemtong C, Yang X, Chang X, Gao J . Nanonization strategies for poorly water-soluble drugs. Drug Discov Today. 2010; 16(7-8):354-60. DOI: 10.1016/j.drudis.2010.02.009. View

12.

Anand P, Sundaram C, Jhurani S, Kunnumakkara A, Aggarwal B . Curcumin and cancer: an "old-age" disease with an "age-old" solution. Cancer Lett. 2008; 267(1):133-64. DOI: 10.1016/j.canlet.2008.03.025. View

13.

Bachhav S, Dighe V, Kotak D, Devarajan P . Rifampicin Lipid-Polymer hybrid nanoparticles (LIPOMER) for enhanced Peyer's patch uptake. Int J Pharm. 2017; 532(1):612-622. DOI: 10.1016/j.ijpharm.2017.09.040. View

14.

Maheshwari R, Singh A, Gaddipati J, Srimal R . Multiple biological activities of curcumin: a short review. Life Sci. 2006; 78(18):2081-7. DOI: 10.1016/j.lfs.2005.12.007. View

15.

Aggarwal B, Kumar A, Bharti A . Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003; 23(1A):363-98. View

16.

Ravindran J, Prasad S, Aggarwal B . Curcumin and cancer cells: how many ways can curry kill tumor cells selectively?. AAPS J. 2009; 11(3):495-510. PMC: 2758121. DOI: 10.1208/s12248-009-9128-x. View

17.

Desai N . Challenges in development of nanoparticle-based therapeutics. AAPS J. 2012; 14(2):282-95. PMC: 3326161. DOI: 10.1208/s12248-012-9339-4. View

18.

Joshi V, Devarajan P . Receptor-mediated hepatocyte-targeted delivery of primaquine phosphate nanocarboplex using a carbohydrate ligand. Drug Deliv Transl Res. 2015; 4(4):353-64. DOI: 10.1007/s13346-014-0200-4. View

19.

Zidan A, Sammour O, Hammad M, Megrab N, Habib M, Khan M . Quality by design: understanding the formulation variables of a cyclosporine A self-nanoemulsified drug delivery systems by Box-Behnken design and desirability function. Int J Pharm. 2006; 332(1-2):55-63. DOI: 10.1016/j.ijpharm.2006.09.060. View

20.

Vibe C, Fenaroli F, Pires D, Wilson S, Bogoeva V, Kalluru R . Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish. Nanotoxicology. 2015; 10(6):680-8. DOI: 10.3109/17435390.2015.1107146. View